Glipizide Tablets 2.5mg (Disha) – for Research Use Only

Glipizide Tablets 2.5mg (Disha) – for Research Use Only

$2.00

Glipizide Tablets 2.5mg from Disha Pharmaceuticals, formulated for experimental research in glucose metabolism and type 2 diabetes models. Supplied in 20 tablets × 4 blister packs per box.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare

Description

Glipizide Tablets 2.5mg, branded by Disha Pharmaceuticals, are oral hypoglycemic agents from the sulfonylurea class, designed for laboratory and experimental purposes only. Commonly used in academic and pre-clinical settings, these tablets are ideal for investigating pancreatic beta-cell stimulation, insulin release mechanisms, and type 2 diabetes research.

This product is not intended for human therapeutic use. It is offered for use in in vitro studies or animal models under controlled laboratory conditions.


Product Parameters

AttributeDetails
Product NameGlipizide Tablets
BrandDisha (??)
Strength2.5mg per tablet
Specification2.5mg × 20 tablets × 4 blisters
Dosage FormTablets
Approval NumberH37022995
Product Code86903944000153
CAS Number29094-61-9
Molecular FormulaC21H27N5O4S
ManufacturerDisha Pharmaceutical Group Co., Ltd.
Packaging UnitBox
Intended UseFor Laboratory/Research Use Only
Barcode6916309659297

Mechanism & Research Applications

Glipizide acts by stimulating pancreatic beta cells to release insulin, effectively lowering blood glucose levels. As a second-generation sulfonylurea, it has a faster onset and shorter duration of action compared to earlier analogs.

In research, it is commonly applied to:

  • Study insulinotropic mechanisms

  • Investigate sulfonylurea receptor (SUR1) binding in pancreatic cells

  • Develop in vivo models of type 2 diabetes mellitus (T2DM)

  • Analyze glucose-lowering pharmacodynamics

Its well-documented action on K<sup>+</sup>-ATP channels in beta cells makes it a benchmark reference compound in diabetes pharmacology research.


Observed Effects in Research

  • Increased endogenous insulin secretion

  • Decreased fasting and postprandial glucose

  • Stimulated islet beta-cell activity

  • Improved glucose tolerance in animal models

  • Enhanced glucose-stimulated insulin secretion (GSIS)


Safety & Handling

  • Research Use Only – Not for diagnostic or therapeutic use

  • Storage – Store in a dry place, protected from light

  • Handling – Wear protective gear during handling

  • Shelf Life – Refer to box label for expiry

  • Disposal – Follow institutional lab waste protocols


Research Use Disclaimer

This product is intended for experimental laboratory research only. It is not for human or veterinary use. Misuse may violate applicable regulations. Not for therapeutic, diagnostic, or dietary use.

Additional information

Weight1 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Glipizide Tablets 2.5mg (Disha) – for Research Use Only”

Your email address will not be published. Required fields are marked *

Q1: What are Glipizide Tablets used for in research?

They are primarily used in experimental models to evaluate blood glucose regulation, insulin secretion, and sulfonylurea receptor activity in the pancreas.

Q2: Are these tablets suitable for human use?

No. These Glipizide Tablets (2.5mg, Disha) are strictly for laboratory use only, not approved for therapeutic or diagnostic use in humans.

Q3: Can I buy this product in bulk?

Yes. Bulk orders are accepted. We support both wholesale and retail distribution for research institutions, labs, and suppliers.

Q4: Is this product suitable for in vivo studies?

Yes, it can be used in animal models for studying glucose metabolism and type 2 diabetes pathology, under ethical research conditions.

Q5: Why choose Glipizide Tablets for type 2 diabetes research?

Because Glipizide is a well-established oral sulfonylurea compound, it's ideal for replicating human insulin secretagogue mechanisms and comparing glucose-lowering efficacy across new drug candidates.


EMI Options

Select at least 2 products
to compare